Akouos, Inc., a precision genetic medicine company, developing gene therapies to restore, improve, and preserve physiologic hearing for individuals. The company's precision genetic medicine platform incorporates a proprietary adeno-associated viral vector library and a novel delivery approach. Its lead product candidate is AK-OTOF, a gene therapy for the treatment of hearing loss due to mutations in the OTOF gene. The company is also developing AK-CLRN1 for the auditory manifestations of Usher syndrome 3A, or USH3A; and AK-antiVEGF for vestibular schwannoma. In addition, its precision genetic medicine platform addresses hearing loss related to genes needed for supporting cell function. Akouos, Inc. was incorporated in 2016 and is based in Boston, Massachusetts.
IPO Year: 2020
Exchange: NASDAQ
Website: akouos.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/29/2022 | $12.00 | Outperform | William Blair |
4 - Akouos, Inc. (0001722271) (Issuer)
4 - Akouos, Inc. (0001722271) (Issuer)
4 - Akouos, Inc. (0001722271) (Issuer)
4 - Akouos, Inc. (0001722271) (Issuer)
4 - Akouos, Inc. (0001722271) (Issuer)
4 - Akouos, Inc. (0001722271) (Issuer)
4 - Akouos, Inc. (0001722271) (Issuer)
4 - Akouos, Inc. (0001722271) (Issuer)
4 - Akouos, Inc. (0001722271) (Issuer)
4 - Akouos, Inc. (0001722271) (Issuer)
William Blair initiated coverage of Akouos with a rating of Outperform and set a new price target of $12.00
HC Wainwright & Co. initiated coverage of Akouos with a rating of Buy and set a new price target of $25.00
BofA Securities downgraded Akouos from Buy to Neutral and set a new price target of $20.00 from $24.00 previously